NCT03732950View on ClinicalTrials.gov

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

December 5, 2023

Study Completion Date

March 6, 2025

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

55905

Mayo Clinic, Rochester

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER